This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Lipoprotein Research Stockholm Ab, The Kitasato Institute. Active years: 2026.
Company Filing History:
1 out of 1 
1 out of 102 Years Active: 2026
Title: Paolo Parini: Innovator in PCSK9 Inhibition
Introduction
Paolo Parini is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). His work has implications for the treatment of various diseases related to cholesterol metabolism.
Latest Patents
Paolo Parini holds a patent for a low-molecular weight compound that acts as a PCSK9 inhibitor. This patent, titled "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and pharmaceutical use therefor," describes a compound that inhibits the functions of PCSK9. The patent outlines the use of this compound, along with its pharmaceutically acceptable salts or solvates, in the prevention or treatment of symptoms, diseases, or disorders associated with PCSK9 functions. He has 1 patent to his name.
Career Highlights
Throughout his career, Paolo Parini has worked with esteemed organizations such as The Kitasato Institute and Lipoprotein Research Stockholm AB. His research has focused on the biochemical pathways involved in lipid metabolism and the role of PCSK9 in cardiovascular diseases.
Collaborations
Paolo has collaborated with notable colleagues, including Mats Eriksson and Tohru Nagamitsu. These partnerships have contributed to the advancement of research in the field of lipidology and pharmacology.
Conclusion
Paolo Parini's innovative work in developing PCSK9 inhibitors showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of cholesterol-related disorders.